

1 UNITED STATES PATENT AND TRADEMARK OFFICE  
2 BEFORE THE PATENT TRIAL AND APPEAL BOARD

3 \_\_\_\_\_  
4 MODERNA THERAPEUTICS, INC., )  
5 Petitioner, ) Case No. IPR2018-00680  
6 v. ) Case No. IPR2018-00739  
7 ) Patent No. 9,404,127  
8 PROTIVA BIOTHERAPEUTICS, )  
9 INC., )  
10 Patent Owner. )  
11 \_\_\_\_\_

12 DEPOSITION UPON ORAL EXAMINATION

13 OF

14 DAVID H. THOMPSON, PhD - VOLUME II  
15 \_\_\_\_\_

16 Taken at 701 Fifth Avenue, Suite 5100

17 Seattle, Washington

18 DATE TAKEN: February 5, 2019

19  
20  
21  
22  
23  
24 REPORTED BY: KATHLEEN HAMILTON, RPR, CRR, CCR 1917

25 JOB NO: 154633

A P P E A R A N C E S

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

FOR THE PETITIONER:

MACLAIN WELLS, ESQ.  
Irell & Manella  
1800 Avenue of the Stars  
Los Angeles, CA 90067

FOR THE PATENT OWNER:

MICHAEL ROSATO, ESQ.  
SONJA GERRARD, ESQ.  
Wilson Sonsini Goodrich & Rosati  
701 Fifth Avenue  
Seattle, WA 98104

ALSO PRESENT:

ANDREW JANOFF, PhD

\* \* \* \* \*

## DEPOSITION OF DAVID H. THOMPSON, PhD

## EXAMINATION INDEX

EXAMINATION BY	PAGE
MR. WELLS.....	213
MR. ROSATO.....	403
MR. WELLS.....	413

## EXHIBIT INDEX

EXHIBITS FOR IDENTIFICATION	PAGE
Exhibit 10 United States Patent Application Publication US 2006/0240554 A1	214
Exhibit 11 Three-Dimensional Imaging of Lipid Gene-Carriers: Membrane Charge Density Controls Universal Transfection Behavior in Lamellar Cationic Liposome-DNA Complexes	229
Exhibit 12 New multivalent cationic lipids reveal bell curve for transfection efficiency versus membrane charge density: Lipid-DNA complexes for gene delivery	240
Exhibit 13 United States Patent Application Publication US 2007/0042031 A1	294
Exhibit 14 United States Patent No. 8,058,069 B2	304
Exhibit 15 Rational design of cationic lipids for siRNA delivery	373
Exhibit 16 Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation Guidance for Industry	379
Exhibit 17 Diffusible-PEG-Lipid Stabilized Plasmid Lipid Particles	384
Exhibit 18 United States Patent No. 8,236,943 B2	388
Exhibit 19 United States Patent Application Publication US 2013/0116307 A1	397

1 DAVID H. THOMPSON, PhD

2 SEATTLE, WASHINGTON; FEBRUARY 5, 2019

3 8:54?a.m.

4 -o0o-

5  
6 E X A M I N A T I O N

7 BY MR. WELLS:

8 Q. You understand that you're still under oath that  
9 you gave yesterday to tell the truth and the whole  
10 truth?

11 A. Yes.

12 Q. And during the breaks yesterday or yesterday  
13 evening, did you discuss your deposition testimony here  
14 today with anybody?

15 A. No.

16 Q. With regard to the `435 patent, do you  
17 understand that one of the grounds involves the 054  
18 reference? Do you recall that?

19 MR. ROSATO: Objection. Form.

20 THE WITNESS: 054?

21 BY MR. WELLS:

22 Q. Oh, actually I should have said `554. I  
23 apologize. That was my error. Let's try that again.

24 A. Yeah.

25 Q. With regard to the `435 patent, do you recall

1                   DAVID H. THOMPSON, PhD

2 one of the references cited was the `554 patent?

3       A.     Correct. Yes, I recall.

4       Q.     Okay. And I'll give you a copy of the `554  
5 patent should you need it. It was previously marked as  
6 Exhibit 1004 to the `435 IPR.

7                   (Exhibit 10 marked.)

8 BY MR. WELLS:

9       Q.     Now, the `554 publication has a formulation  
10 called the L054 formulation. Do you recall that?

11      A.     Yes, I do recall.

12      Q.     And the cationic lipid used in the L054 lipid  
13 mixture is a DMOBA, do you recall that?

14      A.     I recall the structure. I don't... The acronym  
15 I would have to look back and refamiliarize myself, but  
16 it's a -- an aerial ether dimethylamino -- benzyl  
17 dimethylamino lipid.

18      Q.     And if you look at paragraph 122 of your `435  
19 declaration, that has a discussion where you identify  
20 DMOBA as the acronym.

21      A.     Paragraph...?

22      Q.     122.

23      A.     122. Yes; okay I see it.

24      Q.     And do you know whether DMOBA is an ionizable  
25 cationic lipid?

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.